Evidence map›Paper›PMID 34080787›Full record

ArticleCancer medicine2021

Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort.

Helga H Hektoen, Trude E Robsahm, Jo S Stenehjem, Karol Axcrona, Ronnie Babigumira, Alison M Mondul, Randi E Gislefoss, Bettina K Andreassen

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Helga H HektoenDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-2002-0944
Trude E RobsahmDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-1652-7734
Jo S StenehjemDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-1964-5410
Karol AxcronaDepartment of Urology, Akershus University Hospital, Lørenskog, Norway.
Ronnie BabigumiraDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
Alison M MondulDepartment of Epidemiology, University of Michigan, School of Public Health, Ann Arbor, MI, USA.
Randi E GislefossDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
Bettina K AndreassenDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
Cancer Registry of Norway · NOAkershus University Hospital · NOUniversity of Michigan · USUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh circulating levels of vitamin D (25(OH)D) are suggested to reduce the risk of urinary bladder cancer (BC), but the evidence is weak, and several studies lack sufficient adjustment for potential confounders (e.g., smoking, body mass index (BMI), and physical activity). Moreover, few studies have investigated the role of vitamin D-binding protein (DBP) in this context. We conducted a matched nested case-control study including 378 cases and 378 controls within the Norwegian population-based Janus cohort, using serum collected 5-41 years prior to diagnosis, to study 25(OH)D and BC risk, by taking circulating DBP into account.

methodsCox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), for 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, an estimate of unbound (free) 25(OH)D levels. We adjusted for smoking (status and pack-years), BMI, physical activity, education and (mutually) for 25(OH)D and DBP. Restricted cubic splines were employed to examine nonlinear associations.

resultsHigh optimal levels of circulating 25(OH)D (≥100 nmol/L) (HR 0.35, 95% CI 0.19-0.64) were associated with decreased BC risk, when compared with insufficient concentrations (50-74 nmol/L). This association was less pronounced for optimal levels (75-99 nmol/L) (HR = 0.69, 95% CI 0.47-1.01). Moreover, estimated free 25(OH)D, was associated with decreased BC risk for molar ratio 17-21 (HR 0.66, 95% CI 0.44-0.97) and ≥22 (HR 0.50, 95% CI 0.29-0.82), compared to molar ratio 11-16. The HR function for BC risk was not linear, rather reversed u-shaped, with the highest HR at 62.5 nmol/L and 13.5 molar ratio, respectively.

conclusionHigh levels of total and estimated free 25(OH)D were associated with reduced risk of BC, compared with insufficient concentrations. DBP was not associated with BC risk. We did not observe any impact of DBP or any of the studied lifestyle factors on the association between 25(OH)D and BC.

Indexed as

AdultBody Mass IndexCase-Control StudiesCohort StudiesConfidence IntervalsEducational StatusExerciseFemaleHumansMaleMiddle AgedNorwayProportional Hazards ModelsRisk AssessmentSmokingTime Factors25-hydroxyvitamin DVitamin DVitamin D-Binding Proteinbladder cancer riskcancer riskcase-control studyvitamin-binding proteinvitamin D

Identifiers

PMID34080787
PMCPMC8209600
OpenAlexW3164620514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.